Cabo/Ifos in Ewing Sarcoma and Osteosarcoma

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

11 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This study enrolls patients between 5 and 40 years of age with a diagnosis of Ewing sarcoma (including Ewing-like sarcoma) or osteosarcoma that has progressed on or relapsed after upfront initial therapy. The purpose of this study is to find the best dose of a drug called cabozantinib ("the study drug") to give to patients in combination with a routine chemotherapy drug called ifosfamide. 

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at CancerTrials [at] chop.edu or 267-425-5544.

Eligibility & Criteria

IRB #:
22-019876
Official Title:
A phase I trial of Cabozantinib (XL184) in combination with high-dose Ifosfamide in adults and children with relapsed/refractory Ewing sarcoma and osteosarcoma
Study Phase:
Phase I
Eligible Age Range:
5 - 40 Years
Gender:
All
Study Categories:

Visit Criteria

As a participant in the research, you will:

  • Take cabozantinib (the study drug) by mouth once a day, in combination with routine chemotherapy drug ifosfamide given intravenously on days 1-5 of each cycle
  • Complete frequent clinic visits at CHOP Philadelphia campus 
  • Have frequent blood tests
  • Have EKGs and echocardiograms for clinical care purposes
  • Have periodic imaging performed as part of your regular cancer care to evaluate your response to treatment
  • Have research genetic tests (if not previously done clinically)
  • Submit leftover tissue samples to the study repository
  • Have fresh tissue samples collected (if you have a routine biopsy)
Leader
Theodore W. Laetsch

Theodore Laetsch, MD